Drug Profile
524C79
Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Analgesics; Antiretrovirals
- Mechanism of Action Glutamate antagonists; RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis B; HIV infections; Neuralgia; Pain
Most Recent Events
- 24 Aug 1999 Discontinued-I for HIV infections treatment in United Kingdom (Unknown route)
- 24 Aug 1999 Discontinued-Unspecified Phase in Hepatitis B in United Kingdom (Unknown route)
- 24 Aug 1999 Discontinued-Unspecified Phase in Neuralgia in United Kingdom (Unknown route)